Pilihan Terapi yang Tepat untuk Pasien Asma dan Penyakit Paru Obstruktif Kronik (PPOK)

Oleh :

dr. Qorry Amanda, M.Biomed

Pilihan terapi yang tepat untuk pasien asma dan penyakit paru obstruktif kronik (PPOK) adalah kombinasi long-acting beta-2 agonist (LABA) dan inhaled corticosteroid (ICS). Termasuk pemberian inhalasi kombinasi salmeterol/fluticasone propionate. Pada pasien asma, kortikosteroid inhalasi bekerja lebih cepat dengan risiko efek samping lebih rendah daripada kortikosteroid sistemik.[1-3]

Salmeterol merupakan regimen agonis β2 yang berfungsi sebagai bronkodilator kerja panjang, dengan selektivitas yang lebih tinggi pada reseptor β2 jika dibandingkan dengan agonis β2 lainnya, seperti salbutamol maupun formoterol. Sementara itu, fluticasone propionate adalah steroid inhalasi untuk anti-inflamasi, dengan efek yang lebih kuat jika dibandingkan dengan steroid sejenisnya, seperti budesonide, ciclesonide, maupun beclomethasone.[4,5]

Perjalanan Penyakit Asma dan Penyakit Paru Obstruktif Kronik

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Adams BS, Nguyen H. Salmeterol. Treasure Island (FL). StatPearls Publishing; 2022 Jan. https://www.ncbi.nlm.nih.gov/books/NBK557453/
2. Remien K, Bowman A. Fluticasone. Treasure Island (FL): StatPearls Publishing; 2022 Jan. https://www.ncbi.nlm.nih.gov/books/NBK542161/
3. Liang TZ, Chao JH. Inhaled Corticosteroids. Pharmaceuticals. 2022;3(3):514-540. doi:10.3390/ph3030514
4. Lötvall J. Pharmacological similarities and differences between beta2-agonists. Respir Med. 2001 Aug;95 Suppl B:S7-11. doi: 10.1053/rmed.2001.1139. PMID: 11534896.
5. Daley-Yates, P. T. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. British Journal of Clinical Pharmacology, 80(3), 372–380. 2015. doi:10.1111/bcp.12637
6. 2022 Gold Reports - Global Initiative For Chronic Obstructive Lung Disease. GOLD. December 2021. https://goldcopd.org/2022-gold-reports-2/.
7. 2022 Gina Main Report - Global Initiative for Asthma. GINA. July, 2022. https://ginasthma.org/gina-reports/.
8. Pearlman SB, Morgan JA, et al. Pulmonary Emergencies. Essential Emergency Medicine. Published online January 1, 2007:844-913. doi:10.1016/B978-141602971-7.10015-7
9. Barnes PJ, Rennard SI, et al. Asthma and COPD: Basic mechanisms and clinical management. Asthma and COPD: Basic Mechanisms and Clinical Management. October, 2008:1-878. doi:10.1016/B978-0-12-374001-4.X0001-6
10. Bouwens, J.D.M., et al. Diagnostic differentiation between asthma and COPD in primary care using lung function testing. npj Prim. Care Respir. Med. 32, 32 (2022). https://doi.org/10.1038/s41533-022-00298-4
11. D'Urzo AD, Price D, et al. Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care. Can Fam Physician. 2021 Sep;67(9):661-667. doi: 10.46747/cfp.6709661. PMID: 34521707.
12. Kaplan A, FitzGerald JM, et al. Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management. NPJ Prim Care Respir Med. 2020;30(1). doi:10.1038/s41533-020-00205-9
13. Savran O, Godtfredsen NS, et al. Comparison of characteristics between ics-treated copd patients and ics-treated copd patients with concomitant asthma: A study in primary care. International Journal of COPD. 2020;15:931-937. doi:10.2147/COPD.S241561
14. Horvath G, Wanner A. Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. European Respiratory Journal. 2006;27(1):172-187. doi:10.1183/09031936.06.00048605
15. Dahl R, Chuchalin A, et al. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006;100(7):1152-1162. doi:10.1016/j.rmed.2006.03.001
16. Aggarwal B, Jones PW, et al. Direct healthcare costs associated with management of asthma: comparison of two treatment regimens in Indonesia, Thailand and Vietnam. J Asthma. 2021 Mar 27:1-8. doi: 10.1080/02770903.2021.1903915. Epub ahead of print. PMID: 33764239.
17. Deb PK, Abed SN, et al. Aerosols in pharmaceutical product development. In: Drug Delivery Systems. Elsevier; 2019:521-577. doi:10.1016/B978-0-12-814487-9.00011-9
18. Laube BL, Janssens HM, et al. What the pulmonary specialist should know about the new inhalation therapies. European Respiratory Journal. 2011;37(6):1308-1331. doi:10.1183/09031936.00166410
19. Hojo M, Shirai T, et al. Comparison of the clinical effects of combined salmeterol/fluticasone delivered by dry powder or pressurized metered dose inhaler. Pulm Pharmacol Ther. 2016;37:43-48. doi:10.1016/j.pupt.2016.02.004
20. Price D, Roche N, et al. Device type and real-world effectiveness of asthma combination therapy: An observational study. Respir Med. 2011;105(10):1457-1466. doi:10.1016/j.rmed.2011.04.010
21. Mills H, Acquah R, et al. Biochemical Behaviours of Salmeterol/Fluticasone Propionate in Treating Asthma and Chronic Obstructive Pulmonary Diseases (COPD). Emerg Med Int. 2022;2022:1-5. doi:10.1155/2022/2593740
22. Dexa Medica. Respitide (e-Banner). PT. Dexa Medica. 2022
23. Calverley P, Pauwels R, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449-56. doi: 10.1016/S0140-6736(03)12459-2. Erratum in: Lancet. 2003 May 10;361(9369):1660. PMID: 12583942.